News | Breast Imaging | January 27, 2017

Infiniti Research report acknowledges that insurance coverage is still the major issue preventing widespread adoption of tomosynthesis, but states are starting to require coverage

Infiniti Research report, 3-D mammography, growth, challenges, tomosynthesis

January 27, 2017 — Market intelligence firm Infiniti Research released a new report on the growth of 3-D mammography (tomosynthesis) in the United States, highlighting the benefits and acknowledging the barriers to continued adoption.

The following are excerpts from the report:

Mammograms are an essential part of breast cancer detection, and accuracy is vital. While 2-D technology is still frequently used for this process, there now exists a better, more accurate option in 3-D mammography, also known as tomosynthesis.

3-D Mammogram Technology

Innovations in medical imaging technology continue to improve cancer detection, and 3-D mammography is among them. As with its 2-D counterpart, the 3-D machine still needs to compress the breast to take a reading. But instead of remaining stationary, it rotates through an arc, taking multiple images to create a three-dimensional image of the breast. This allows it to deliver clearer and more accurate results than its predecessor. It provides a clearer image of the breast tissue, and is better able to view dense tissue, thereby reducing false positives and false negatives. This technology has increased early breast cancer detections by at least 40 percent, making the cancer easier to treat and eliminate.

Health Insurance: Setbacks and Opportunities

Despite all of the benefits of these machines, many people have been unable to take advantage of them. In the United States, for example, many health insurance companies will not cover procedures that use this new technology, despite it often being more effective. While Medicare and Medicaid do cover it, private insurers do not. Patients can therefore be forced to settle for a 2-D mammogram even when it is not the best option.

This is changing in at least one state, however. Connecticut has brought in a new law this year that requires insurers to cover 3-D mammograms if the patient asks for them. While the state’s Insurance Department argues that this will be very costly to implement, supporters of the law disagree. Although the initial cost of acquiring new equipment will be high, the accuracy of these tests will eliminate the need for many 2-D tests. The costs should also fall as the equipment and tests become more prevalent.

For more information: www.infinitiresearch.com


Related Content

News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | Artificial Intelligence

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have ...

Time December 10, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
Subscribe Now